The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group ...

After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...

Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...

What Is Palsonify, and Why Does It Matter? Palsonify (paltusotine) is a new once-daily oral medicine approved to treat adults with acromegaly who either didn’t get much help from surgery or cannot ...

Crinetics Pharmaceuticals (NASDAQ:CRNX) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly, a rare condition characterized by ...

We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies that soared by double- and triple-digits last ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on ...

Sept 25 (Reuters) - The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' (CRNX.O), opens new tab drug to treat a rare hormonal disorder on Thursday, making it the first once-daily ...

Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the ...

Within the hormone type segment, Hypothalamic Peptide Hormones stand out as the market leader, commanding 59.6% of total ...